Titre : Antigène CD63

Antigène CD63 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Life Expectancy
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Antigène CD63 : Questions médicales les plus fréquentes", "headline": "Antigène CD63 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Antigène CD63 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-06", "dateModified": "2025-05-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Antigène CD63" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines du transport vésiculaire", "url": "https://questionsmedicales.fr/mesh/D033921", "about": { "@type": "MedicalCondition", "name": "Protéines du transport vésiculaire", "code": { "@type": "MedicalCode", "code": "D033921", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.990" } } }, "about": { "@type": "MedicalCondition", "name": "Antigène CD63", "alternateName": "Tetraspanin 30", "code": { "@type": "MedicalCode", "code": "D060149", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Thorsten Lang", "url": "https://questionsmedicales.fr/author/Thorsten%20Lang", "affiliation": { "@type": "Organization", "name": "Department of Membrane Biochemistry, Life & Medical Sciences (LIMES) Institute, University of Bonn, Carl-Troll-Straße 31, 53115 Bonn, Germany. Electronic address: thorsten.lang@uni-bonn.de." } }, { "@type": "Person", "name": "Annemiek B van Spriel", "url": "https://questionsmedicales.fr/author/Annemiek%20B%20van%20Spriel", "affiliation": { "@type": "Organization", "name": "Department of Tumor Immunology and." } }, { "@type": "Person", "name": "Jana Jankovičová", "url": "https://questionsmedicales.fr/author/Jana%20Jankovi%C4%8Dov%C3%A1", "affiliation": { "@type": "Organization", "name": "Laboratory of Reproductive Physiology, Center of Biosciences, Institute of Animal Biochemistry and Genetics, Slovak Academy of Sciences, Bratislava, Slovak Republic." } }, { "@type": "Person", "name": "Petra Sečová", "url": "https://questionsmedicales.fr/author/Petra%20Se%C4%8Dov%C3%A1", "affiliation": { "@type": "Organization", "name": "Laboratory of Reproductive Physiology, Center of Biosciences, Institute of Animal Biochemistry and Genetics, Slovak Academy of Sciences, Bratislava, Slovak Republic." } }, { "@type": "Person", "name": "Jana Antalíková", "url": "https://questionsmedicales.fr/author/Jana%20Antal%C3%ADkov%C3%A1", "affiliation": { "@type": "Organization", "name": "Laboratory of Reproductive Physiology, Center of Biosciences, Institute of Animal Biochemistry and Genetics, Slovak Academy of Sciences, Bratislava, Slovak Republic. jana.antalikova@savba.sk." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Divergences and gaps in life expectancy and health-adjusted life expectancy in Mexico: Contribution analysis of the Global Burden of Disease Study 2019.", "datePublished": "2023-11-06", "url": "https://questionsmedicales.fr/article/37930966", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0293881" } }, { "@type": "ScholarlyArticle", "name": "Changes and Trend Disparities in Life Expectancy and Health-Adjusted Life Expectancy Attributed to Disability and Mortality From 1990 to 2019 in China.", "datePublished": "2022-07-18", "url": "https://questionsmedicales.fr/article/35923968", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2022.925114" } }, { "@type": "ScholarlyArticle", "name": "[Life expectancy and Covid: Setting the record straight].", "datePublished": "2022-12-13", "url": "https://questionsmedicales.fr/article/36692277", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1051/medsci/2022158" } }, { "@type": "ScholarlyArticle", "name": "Life expectancy changes since COVID-19.", "datePublished": "2022-10-17", "url": "https://questionsmedicales.fr/article/36253520", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41562-022-01450-3" } }, { "@type": "ScholarlyArticle", "name": "Total life expectancy and disability-free life expectancy and differences attributable to cigarettes' smoking among Chinese middle-aged and older adults.", "datePublished": "2024-08-08", "url": "https://questionsmedicales.fr/article/39118038", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12877-024-05007-z" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Protéines du transport vésiculaire", "item": "https://questionsmedicales.fr/mesh/D033921" }, { "@type": "ListItem", "position": 6, "name": "Antigène CD63", "item": "https://questionsmedicales.fr/mesh/D060149" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Antigène CD63 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Antigène CD63", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Antigène CD63", "description": "Comment détecte-t-on l'antigène CD63 ?\nQuels tests sont utilisés pour le CD63 ?\nLe CD63 est-il un marqueur de maladie ?\nQuelle est l'importance du CD63 dans le diagnostic ?\nLe CD63 est-il spécifique à certaines cellules ?", "url": "https://questionsmedicales.fr/mesh/D060149?mesh_terms=Life+Expectancy&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Antigène CD63", "description": "Quels symptômes sont liés à une activation du CD63 ?\nLe CD63 est-il associé à des maladies spécifiques ?\nQuels signes cliniques peuvent indiquer un problème avec le CD63 ?\nLe CD63 influence-t-il la réponse immunitaire ?\nPeut-on mesurer le CD63 dans le sang ?", "url": "https://questionsmedicales.fr/mesh/D060149?mesh_terms=Life+Expectancy&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Antigène CD63", "description": "Comment prévenir les réactions liées au CD63 ?\nY a-t-il des mesures préventives pour les maladies liées au CD63 ?\nLe dépistage précoce est-il utile pour le CD63 ?\nLes vaccinations aident-elles à prévenir les problèmes liés au CD63 ?\nL'éducation des patients est-elle importante pour le CD63 ?", "url": "https://questionsmedicales.fr/mesh/D060149?mesh_terms=Life+Expectancy&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Antigène CD63", "description": "Comment traiter une réaction liée au CD63 ?\nLe CD63 est-il une cible thérapeutique ?\nQuels médicaments affectent le CD63 ?\nLe CD63 est-il impliqué dans des traitements anticancéreux ?\nY a-t-il des traitements spécifiques pour le CD63 ?", "url": "https://questionsmedicales.fr/mesh/D060149?mesh_terms=Life+Expectancy&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Antigène CD63", "description": "Quelles complications peuvent survenir avec le CD63 ?\nLe CD63 est-il lié à des complications auto-immunes ?\nComment les complications liées au CD63 sont-elles gérées ?\nLe CD63 peut-il aggraver d'autres conditions médicales ?\nY a-t-il des risques à long terme liés au CD63 ?", "url": "https://questionsmedicales.fr/mesh/D060149?mesh_terms=Life+Expectancy&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Antigène CD63", "description": "Quels sont les facteurs de risque pour l'activation du CD63 ?\nL'âge influence-t-il le CD63 ?\nLe stress affecte-t-il le CD63 ?\nY a-t-il des prédispositions génétiques pour le CD63 ?\nL'environnement joue-t-il un rôle dans l'activation du CD63 ?", "url": "https://questionsmedicales.fr/mesh/D060149?mesh_terms=Life+Expectancy&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment détecte-t-on l'antigène CD63 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'antigène CD63 est détecté par des techniques comme la cytométrie en flux." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le CD63 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests immunologiques comme l'immunofluorescence peuvent être utilisés." } }, { "@type": "Question", "name": "Le CD63 est-il un marqueur de maladie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le CD63 peut être un marqueur dans certaines pathologies, notamment les allergies." } }, { "@type": "Question", "name": "Quelle est l'importance du CD63 dans le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Il aide à identifier certaines cellules immunitaires et leur activation." } }, { "@type": "Question", "name": "Le CD63 est-il spécifique à certaines cellules ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est principalement exprimé sur les mastocytes et les plaquettes." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une activation du CD63 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une activation excessive peut entraîner des réactions allergiques ou inflammatoires." } }, { "@type": "Question", "name": "Le CD63 est-il associé à des maladies spécifiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est souvent associé à des maladies allergiques et auto-immunes." } }, { "@type": "Question", "name": "Quels signes cliniques peuvent indiquer un problème avec le CD63 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'urticaire ou l'anaphylaxie peuvent être observés." } }, { "@type": "Question", "name": "Le CD63 influence-t-il la réponse immunitaire ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il joue un rôle clé dans la modulation de la réponse immunitaire." } }, { "@type": "Question", "name": "Peut-on mesurer le CD63 dans le sang ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux de CD63 peuvent être mesurés dans le sérum pour évaluer l'activation." } }, { "@type": "Question", "name": "Comment prévenir les réactions liées au CD63 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les allergènes connus peut aider à prévenir les réactions liées au CD63." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives pour les maladies liées au CD63 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des stratégies de gestion des allergies peuvent réduire les risques de réactions." } }, { "@type": "Question", "name": "Le dépistage précoce est-il utile pour le CD63 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un dépistage précoce peut aider à identifier les risques d'allergies." } }, { "@type": "Question", "name": "Les vaccinations aident-elles à prévenir les problèmes liés au CD63 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent réduire le risque de maladies allergiques." } }, { "@type": "Question", "name": "L'éducation des patients est-elle importante pour le CD63 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, informer les patients sur les allergies peut aider à prévenir les réactions." } }, { "@type": "Question", "name": "Comment traiter une réaction liée au CD63 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les antihistaminiques sont souvent utilisés pour traiter les réactions allergiques." } }, { "@type": "Question", "name": "Le CD63 est-il une cible thérapeutique ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des thérapies ciblant le CD63 sont en développement pour certaines maladies." } }, { "@type": "Question", "name": "Quels médicaments affectent le CD63 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments immunosuppresseurs peuvent influencer l'expression du CD63." } }, { "@type": "Question", "name": "Le CD63 est-il impliqué dans des traitements anticancéreux ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est étudié comme un potentiel marqueur pour des thérapies anticancéreuses." } }, { "@type": "Question", "name": "Y a-t-il des traitements spécifiques pour le CD63 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de traitements spécifiques ciblant uniquement le CD63." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le CD63 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des chocs anaphylactiques peuvent survenir en cas d'activation excessive." } }, { "@type": "Question", "name": "Le CD63 est-il lié à des complications auto-immunes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une activation anormale du CD63 peut contribuer à des maladies auto-immunes." } }, { "@type": "Question", "name": "Comment les complications liées au CD63 sont-elles gérées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont gérées par des traitements d'urgence et des soins médicaux appropriés." } }, { "@type": "Question", "name": "Le CD63 peut-il aggraver d'autres conditions médicales ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une activation excessive peut aggraver des conditions comme l'asthme." } }, { "@type": "Question", "name": "Y a-t-il des risques à long terme liés au CD63 ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des risques à long terme incluent des maladies chroniques si non gérées correctement." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour l'activation du CD63 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents d'allergies et d'expositions environnementales sont des facteurs de risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le CD63 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines populations, comme les enfants, peuvent être plus sensibles aux allergies." } }, { "@type": "Question", "name": "Le stress affecte-t-il le CD63 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut exacerber les réactions allergiques et l'activation du CD63." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques pour le CD63 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs génétiques peuvent influencer la réponse immunitaire et le CD63." } }, { "@type": "Question", "name": "L'environnement joue-t-il un rôle dans l'activation du CD63 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs environnementaux comme la pollution peuvent augmenter le risque." } } ] } ] }

Sources (10000 au total)

Divergences and gaps in life expectancy and health-adjusted life expectancy in Mexico: Contribution analysis of the Global Burden of Disease Study 2019.

Life expectancy (LE) and Health-adjusted life expectancy (HALE) are summary indicators that reflect a population's general life conditions and measure inequities in health outcomes. The objective of t... A secondary analysis was performed based on the Global Burden of Disease, Injuries, and Risk Factors Study (GBD). Data were obtained for LE (by sex and state) and HALE (by sex, age group, and state) f... LE and HALE had an absolute increase of 6.7% and 6.4% from 1990 to 2019, mainly among women, although they spent more years in poor health (11.8 years) than men. The patterns of LE and HALE were heter... Progress in LE and HALE has slowed in recent years; HALE has even had setbacks in some states. Gaps between men and women, as well as between states, are persistent. Public and population policymaking...

Changes and Trend Disparities in Life Expectancy and Health-Adjusted Life Expectancy Attributed to Disability and Mortality From 1990 to 2019 in China.

This study aims to investigate sex, age, and cause-specific contributions to changes and trend disparities in life expectancy (LE) and health-adjusted life expectancy (HALE) attributed to disability a... Contributions of disability and mortality to changes and trend disparities in LE and HALE were estimated with standard abridged life table, Sullivan's method, and decomposition method, using retrospec... From 1990 to 2019, LE and HALE increased by 10.49 and 8.71 years for both sexes, mainly due to noncommunicable diseases (NCDs) (5.83 years, 55.58% for LE and 6.28 years, 72.10% for HALE). However, HIV... The LE and HALE in China have grown rapidly over the past few decades, mainly attributed to NCDs. It is necessary to further reduce the negative mortality effect of HIV/AIDS, lung cancer, colon and re...

Total life expectancy and disability-free life expectancy and differences attributable to cigarettes' smoking among Chinese middle-aged and older adults.

Middle-aged and older adults smoking for years are afflicted by smoking-related diseases and functional limitations; however, little is known about the effect of smoking on nonfatal conditions in midd... Data were drawn from the China Health and Retirement Longitudinal Study (CHARLS), 2011-2018, with a total sample of 16,859 individuals aged 45 years or older involved in the final analysis. The Activi... At baseline, 28.9% of participants were current smokers, 8.5% were former smokers, and 62.6% never smoked. Approximately 5.6% were identified with ADL disability. Both current smokers and former smoke... Never smokers live longer and healthier than current smokers and persons who quit smoking. Smoking was associated with greater reductions in TLE and DFLE among men. However, educational attainment mig...

Life expectancy and healthy life expectancy of Korean registered disabled by disability type in 2014-2018: Korea National Rehabilitation Center database.

Conducting a distinct comparison between the life expectancy (LE) and healthy life expectancy (HALE) of people with disabilities (PWDs) and the general population is necessary due to the various envir... We used aggregated data of registered PWDs from the Korea National Rehabilitation Center database between 2014 and 2018. Overall, 345,595 deaths were included among 12,627,428 registered PWDs. First, ... The calculated LE/HALE-NHIS (years) at registration in males and females were 81.32/73.32 and 87.38/75.58, 68.54/58.98 and 71.43/59.24, 73.87/65.43 and 78.25/67.51, and 61.53/50.48 and 62.41/49.72 yea... Males with disabilities had shorter LE and HALE at registration than females, except for those with severe disabilities, and there were variabilities in the LE based on the disability types....

Trends in cancer-free working life expectancy based on health insurance data from Germany-Is the increase as strong as in working life expectancy?

Against the backdrop of population ageing, governments are facing the need to raise the statutory retirement age. In this context, the question arises whether these extra years added to working life w... The analyses are based on the data of a large German health insurer covering annually about 2 million individuals. Cancer-free WLE is calculated based on multistate life tables and reported for three ... While labour force participation increased, cancer incidence rates decreased over time. Cancer-free WLE at age 18 increased by 2.5 years in men and 6.3 years in women (age 50: 1.3 years in men, 2.4 ye... The increase in WLE is accompanied by an increase in cancer-free WLE. However, the subgroups considered have not benefitted equally from this positive development. Among men at higher working age, WLE...

Unhealthy lifestyles and regional differences in life expectancy in Russia.

The study seeks to identify the impact of smoking, sports participation, and alcohol consumption on life expectancy of men and women in Russian regions.... We use official data for 2014-2020 for 77 Russian regions. We estimate factors related to life expectancy separately for men and women to account for differences in their life expectancy and lifestyle... We run fixed-effect models to estimate regional life expectancy depending on smoking, alcohol consumption, sport participation, healthcare characteristics, and demographical and economic factors.... Life expectancy was negatively associated with alcohol consumption and smoking and positively with sport participation: a 1-L increase in alcohol consumption was attributed to a 1.6-month decrease in ... We find significant variation in life expectancy across Russian regions that can be partly explained by unhealthy lifestyles. We suggest that policies aimed at improving national health in diverse cou...